An overview of current and future therapeutic strategies for the treatment of primary sclerosing cholangitis

Introduction: Primary sclerosing cholangitis (PCS) is a cholestatic liver disease characterized by chronic destruction and stricturing of the biliary tree, leading to fibrosis and liver cirrhosis. The underlying mechanisms of the disease are poorly understood. Areas covered: Multiple agents with various pharmacological activities have been examined in PSC patients with disappointing results. Ursodeoxycholic acid (UDCA) is by far the most extensively studied agent in PSC. Large prospective trials have failed to demonstrate a positive long-term effect of UDCA in patients with PSC. Antimicrobials have been examined in PSC patients but long-term outcome data are lacking. Immunosuppressive agents were tested in patients with PSC but the majority of these agents were associated with adverse side effects. Nor-UDCA is a newly emerging C23 homolog of UDCA that has shown promising results in experimental studies. The farnesoid X receptor agonists are an attractive class of drugs and are currently being studied in patients with primary biliary cirrhosis. Antifibrotic agents have yielded encouraging results in animal models of PSC but are yet to be evaluated in humans. Expert opinion: Currently, there is no effective treatment for PSC. It is our hope that the newly discovered potential therapeutic routes will lead to the discovery of a curative agent for this debilitating disease.

[1]  S. Holdenrieder,et al.  Soluble intracellular adhesion molecule, M30 and M65 as serum markers of disease activity and prognosis in cholestatic liver diseases , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  M. Manns,et al.  Calprotectin in Bile: A Disease Severity Marker in Patients With Primary Sclerosing Cholangitis , 2014, Journal of clinical gastroenterology.

[3]  F. Carrat,et al.  Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. , 2014, Gastroenterology.

[4]  F. Carrat,et al.  AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Radiologic Course of Primary Sclerosing Cholangitis: Assessment by Three-Dimensional Magnetic Resonance Cholangiography and Predictive Features of Progression , 2013 .

[5]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[6]  Emma M. B. Weeding,et al.  Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis ‐ a pilot study , 2013, Alimentary pharmacology & therapeutics.

[7]  A. Schoepfer,et al.  Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes , 2013, Inflammatory bowel diseases.

[8]  K. Nadeau,et al.  Immunomodulatory Effect of Vancomycin on Treg in Pediatric Inflammatory Bowel Disease and Primary Sclerosing Cholangitis , 2013, Journal of Clinical Immunology.

[9]  S. Vermeire,et al.  Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease , 2012, Inflammatory bowel diseases.

[10]  Hiroshi Suzuki,et al.  Ursodeoxycholic acid stimulates the formation of the bile canalicular network. , 2012, Biochemical pharmacology.

[11]  R. Poupon.  Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. , 2012, Clinics and research in hepatology and gastroenterology.

[12]  J. Prieto,et al.  Ursodeoxycholic Acid Is Conjugated with Taurine to Promote Secretin-Stimulated Biliary Hydrocholeresis in the Normal Rat , 2011, PloS one.

[13]  K. Lindor,et al.  High‐dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis , 2011, Alimentary pharmacology & therapeutics.

[14]  K. Lindor,et al.  High-Dose Ursodeoxycholic Acid Is Associated With the Development of Colorectal Neoplasia in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis , 2011, The American Journal of Gastroenterology.

[15]  G. Kaplan,et al.  Incidence of primary sclerosing cholangitis: A systematic review and meta‐analysis , 2011, Hepatology.

[16]  C. Weston,et al.  Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity , 2011, Hepatology.

[17]  Margarete Odenthal,et al.  β-Adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis , 2011, Laboratory Investigation.

[18]  M. Manos,et al.  Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C , 2011, Journal of viral hepatitis.

[19]  G. Alexander,et al.  Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease , 2010, Gut.

[20]  A. Kahraman,et al.  Apoptosis in Immune-Mediated Liver Diseases , 2010, Digestive Diseases.

[21]  G. Gores,et al.  Diagnosis and management of primary sclerosing cholangitis , 2010, Hepatology.

[22]  D. Foell,et al.  The endogenous Toll–like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer , 2009, Journal of leukocyte biology.

[23]  K. Zatloukal,et al.  Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice , 2009, Hepatology.

[24]  K. Kikuchi,et al.  Ursodeoxycholic acid reduces CpG‐induced IgM production in patients with primary biliary cirrhosis , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[25]  Natalie J Torok,et al.  Minocycline in the Treatment of Patients With Primary Sclerosing Cholangitis: Results of a Pilot Study , 2009, The American Journal of Gastroenterology.

[26]  A. West,et al.  Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay , 2008, Hepatology.

[27]  D. Schuppan,et al.  Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. , 2008, Gastroenterology.

[28]  F. Vleggaar,et al.  Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study , 2008, European journal of gastroenterology & hepatology.

[29]  K. Cox,et al.  Long-term Treatment of Primary Sclerosing Cholangitis in Children With Oral Vancomycin: An Immunomodulating Antibiotic , 2008, Journal of pediatric gastroenterology and nutrition.

[30]  D. Hommes,et al.  A Double-blind, Placebo-controlled, Randomized Study of Infliximab in Primary Sclerosing Cholangitis , 2008, Journal of clinical gastroenterology.

[31]  K. Boberg,et al.  The natural history of small-duct primary sclerosing cholangitis. , 2008, Gastroenterology.

[32]  B. Petersen,et al.  Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. , 2008, Gastroenterology.

[33]  E. Björnsson,et al.  Immunoglobulin G4 associated cholangitis: Description of an emerging clinical entity based on review of the literature , 2007, Hepatology.

[34]  J. Talwalkar,et al.  Tacrolimus for the treatment of primary sclerosing cholangitis , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[35]  A. Befeler,et al.  High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis , 2007, Current gastroenterology reports.

[36]  K. Zatloukal,et al.  24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. , 2006, Gastroenterology.

[37]  K. Boberg,et al.  High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. , 2005, Gastroenterology.

[38]  K. Chayama,et al.  Therapeutic Effect of Repeated Natural Killer T Cell Stimulation in Mouse Cholangitis Complicated by Colitis , 2005, Digestive Diseases and Sciences.

[39]  Y. Baruch,et al.  Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. , 2005, Journal of hepatology.

[40]  K. Lankarani.  Mycophenolate mofetil for the treatment of primary sclerosing cholangitis , 2005, Alimentary pharmacology & therapeutics.

[41]  D. Schuppan,et al.  Serum markers detect the presence of liver fibrosis: a cohort study. , 2004, Gastroenterology.

[42]  M. Färkkilä,et al.  Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo‐controlled trial , 2004, Hepatology.

[43]  A. Sanyal,et al.  A prospective, randomized‐controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis , 2004, Alimentary pharmacology & therapeutics.

[44]  U. Meyer,et al.  Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. , 2004, Pharmacogenetics.

[45]  D. Adams,et al.  Lymphocyte homing in the pathogenesis of extra-intestinal manifestations of inflammatory bowel disease. , 2004, Clinical medicine.

[46]  K. Lindor,et al.  Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis , 2004, American Journal of Gastroenterology.

[47]  U. Beuers,et al.  Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. , 2004, Clinics in liver disease.

[48]  S. Scalia,et al.  Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration , 2003, Gut.

[49]  B. Staels,et al.  FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. , 2003, Gastroenterology.

[50]  T. Willson,et al.  6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.

[51]  H. Bernstein,et al.  Activation of the Metallothionein IIA Promoter and Other Key Stress Response Elements by Ursodeoxycholate in HepG2 Cells: Relevance to the Cytoprotective Function of Ursodeoxycholate , 2002, Pharmacology.

[52]  B. Chatterjee,et al.  Dehydroepiandrosterone Sulfotransferase Gene Induction by Bile Acid Activated Farnesoid X Receptor* , 2001, The Journal of Biological Chemistry.

[53]  R. Chapman,et al.  A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. , 2001, Gastroenterology.

[54]  M. Makishima,et al.  Human Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor/Bile Acid Receptor* , 2001, The Journal of Biological Chemistry.

[55]  M. Makishima,et al.  The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. , 2001, Gastroenterology.

[56]  D. Adams,et al.  MAdCAM‐1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM‐1 in chronic inflammatory liver disease) , 2001, Hepatology.

[57]  S. Kawa,et al.  Sclerosing pancreato-cholangitis responsive to corticosteroid therapy: report of 2 case reports and review. , 2001, Gastrointestinal endoscopy.

[58]  W. Hop,et al.  No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study , 2001, European journal of gastroenterology & hepatology.

[59]  A. Saven,et al.  An Open-label Pilot Trial of Cladibrine (2-Chlorodeoxyadenosine) in Patients with Primary Sclerosing Cholangitis , 2000 .

[60]  N. LaRusso,et al.  A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis , 2000, American Journal of Gastroenterology.

[61]  K. Batts,et al.  Oral budesonide in the treatment of primary sclerosing cholangitis. , 2000 .

[62]  N. Afdhal.  Gallbladder and Biliary Tract Diseases , 2000 .

[63]  W. Hop,et al.  Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study , 2000, American Journal of Gastroenterology.

[64]  R. N. Macsween,et al.  Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease. , 1999, Liver.

[65]  E. Björnsson,et al.  CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. , 1999, Liver.

[66]  T. Okanoue,et al.  Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. , 1999, Biochemical and biophysical research communications.

[67]  K. Boberg,et al.  HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. , 1999, Tissue antigens.

[68]  K. Batts,et al.  Recurrence of primary sclerosing cholangitis following liver transplantation , 1999, Hepatology.

[69]  K. Cox,et al.  Oral Vancomycin: Treatment of Primary Sclerosing Cholangitis in Children with Inflammatory Bowel Disease , 1998, Journal of Pediatric Gastroenterology and Nutrition.

[70]  Y. Kinoshita,et al.  Primary sclerosing pancreatitis and cholangitis , 1998, International journal of pancreatology : official journal of the International Association of Pancreatology.

[71]  K. Tanikawa,et al.  Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. , 1998, Journal of hepatology.

[72]  W. Hop,et al.  Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. , 1998, Journal of hepatology.

[73]  G. Bringmann,et al.  The Atropisomer-Selective Ring Cleavage of Helically Distorted, Configuratively Unstable Biaryl Lactones with a Chiral Metallated N-Nucleophile - the Complete PM3 Mechanistic Course and its Video Presentation , 1998 .

[74]  C. Steer,et al.  Ursodeoxycholic Acid May Inhibit Deoxycholic Acid-Induced Apoptosis by Modulating Mitochondrial Transmembrane Potential and Reactive Oxygen Species Production , 1998, Molecular medicine.

[75]  C. Mackay,et al.  Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. , 1997, The American journal of pathology.

[76]  K. Lindor.  Ursodiol for Primary Sclerosing Cholangitis , 1997 .

[77]  W. Stremmel,et al.  Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. , 1997, Journal of hepatology.

[78]  R. Jian,et al.  Ileal absorption of bile acids in patients with chronic cholestasis , 1996, Digestive Diseases and Sciences.

[79]  D. V. van Thiel,et al.  Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. , 1996, Hepato-gastroenterology.

[80]  G. Gerken,et al.  Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. , 1996, Journal of hepatology.

[81]  Å. Danielsson,et al.  Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. , 1996, Gut.

[82]  G. Gores,et al.  Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. , 1996, The American journal of gastroenterology.

[83]  J. Boyer,et al.  Pseudotumor of the pancreas associated with retroperitoneal fibrosis: a dramatic response to corticosteroid therapy. , 1995, The American journal of gastroenterology.

[84]  A. Stiehl.  Intestinal absorption of bile acids: effect of ursodeoxycholic acid treatment. , 1995, The Italian journal of gastroenterology.

[85]  Å. Danielsson,et al.  Colchicine treatment of primary sclerosing cholangitis. , 1995, Gastroenterology.

[86]  R. Chapman,et al.  Adhesion molecule expression in primary sclerosing cholangitis and primary biliary cirrhosis. , 1995, Gut.

[87]  M. Kaplan,et al.  A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. , 1994, Gastroenterology.

[88]  U. Leuschner,et al.  Molecular aspects of membrane stabilization by ursodeoxycholate , 1993 .

[89]  R. Wiesner,et al.  Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. , 1993, Gut.

[90]  R. Laitt,et al.  Sclerosing cholangitis associated with multifocal fibrosis: a case report. , 1992, Gut.

[91]  T. Sauerbruch,et al.  Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo‐controlled trial , 1992, Hepatology.

[92]  Y. Matsumura,et al.  Immunomodulatory effects of ursodeoxycholic acid on immune responses , 1992, Hepatology.

[93]  H. Waldum.  Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. , 1992, Journal of hepatology.

[94]  U. Spengler,et al.  Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease , 1992, Hepatology.

[95]  J. Senior,et al.  Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: A 30‐month pilot study , 1991, Hepatology.

[96]  R. Wiesner,et al.  Current concepts in cell‐mediated hepatic allograft rejection leading to ductopenia and liver failure , 1991, Hepatology.

[97]  B. Portmann,et al.  Natural history and prognostic variables in primary sclerosing cholangitis. , 1991, Gastroenterology.

[98]  R. Clark,et al.  Biliary tract disease in rats with experimental small bowel bacterial overgrowth , 1991, Hepatology.

[99]  R. Sartor,et al.  Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. , 1991, Gastroenterology.

[100]  P. Couzigou,et al.  Ursodeoxycholic acid for primary sclerosing cholangitis. , 1990, Journal of hepatology.

[101]  P. Grambsch,et al.  Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis , 1989, Hepatology.

[102]  A. Zinsmeister,et al.  Prospective trial of penicillamine in primary sclerosing cholangitis. , 1988, Gastroenterology.

[103]  M. Broom,et al.  Enterohepatic circulation of bacterial chemotactic peptide in rats with experimental colitis. , 1988, Gastroenterology.

[104]  R. Chapman,et al.  Association of primary sclerosing cholangitis with HLA-B8. , 1983, Gut.

[105]  N. LaRusso,et al.  Oral Nicotine in Treatment of Primary Sclerosing Cholangitis (A Pilot Study) , 2004, Digestive Diseases and Sciences.

[106]  M. Kaplan,et al.  A Pilot Study of Etanercept in the Treatment of Primary Sclerosing Cholangitis , 2004, Digestive Diseases and Sciences.

[107]  R. Wiesner,et al.  Pirfenidone in the Treatment of Primary Sclerosing Cholangitis , 2004, Digestive Diseases and Sciences.

[108]  A. Saven,et al.  An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. , 2000, Journal of clinical gastroenterology.

[109]  T. Therneau,et al.  Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. , 1999, Hepatology.

[110]  K. Lindor.  Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. , 1997, The New England journal of medicine.

[111]  D. V. van Thiel,et al.  Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. , 1995, The American journal of gastroenterology.

[112]  J. de Caestecker,et al.  Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. , 1994, Gastroenterology.

[113]  W. Hofmann,et al.  Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. , 1994, Journal of hepatology.

[114]  U. Leuschner,et al.  Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]. , 1993, Gastroenterology.

[115]  R. Wiesner,et al.  The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. , 1991, The American journal of gastroenterology.